
EIDD-1931 - Antivirale Therapie bei Feliner Infektiöser Peritonitis (FIP)
Bewertung schreibenKörpergewicht der Katze wählen
Our capsules deliver pure EIDD-1931, the active antiviral metabolite of molnupiravir, in a formulation designed for feline physiology. EIDD-1931 does not require metabolization in the liver, thus significantly reducing liver stress typically associated with prolonged Molnupiravir (EIDD-2801) treatments. By using EIDD-1931 directly—rather than modifying human molnupiravir capsules— Our EIDD-1931 capsules provide a more potent, precise, and consistent veterinary-appropriate approach to FIP care, while significantly reducing any potential side effects associated with prolonged Molnupiravir treatments.
Purpose-Built Feline Formulation
Each capsule contains 15 mg of EIDD-1931, equivalent in activity to approximately 66 mg of molnupiravir (EIDD-2801).
This formulation is optimized for:
Feline metabolic rate
Gastrointestinal absorption profile
Reliable dose–response performance
The result is accurate, predictable antiviral activity with reduced variability compared to human-intended products.
Proven Antiviral Potency
Published research demonstrates that:
EIDD-1931 exhibits up to 5.6× greater in-vitro antiviral potency compared with molnupiravir (EIDD-2801).
EIDD-1931 demonstrates 7.3× higher potency than GS-441524 under similar test conditions.
This potency advantage enables therapeutic efficacy at lower milligram doses, supporting improved tolerability and rapid clinical response.
Reference:
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity Against Enterovirus Infections In Vitro and In Vivo. https://www.mdpi.com/1999-4915/14/6/1142
Comprehensive Support Across FIP Presentations
Our EIDD-1931 capsules are formulated for all major forms of FIP, including:
Wet FIP (effusive)
Dry FIP (non-effusive)
Mixed or transitional presentations
Additional formulation benefits:
Optimized for feline metabolism and tissue penetration
Highly consistent blood-level performance
Designed to support low relapse incidence when used according to veterinary guidance
Precision, Safety & Confidence in Every Dose
Your cat receives an advanced, veterinary-formulated antiviral designed for targeted and reliable performance:
Scientifically grounded formulation
Consistent mg-per-kg dosing
No need to modify human medications
Backed by modern antiviral research
Compared to human 200mg molnupiravir, our capsules provide a clearer, more controlled path to FIP recovery, supporting your cat’s return to comfort, vitality, and quality of life.
Produktbeschreibung
Wirkstoff: EIDD-1931
Hilfsstoffe: Calciumhydrogenphosphat, Magnesiumstearat
Darreichungsform: Kapseln Größe 3
Anwendungsgebiet: ideal für Katzen mit effusiver (feuchter) und nicht effusiver (trockener) Feliner Infektiöser Peritonitis (FIP)
Packungsinhalt: 60 Kapseln mit je 15 mg EIDD-1931
Dosierung: 1 Kapsel alle 12 Stunden pro 2,5 kg Körpergewicht, möglichst auf nüchternen Magen.
Erbricht die Katze innerhalb von 30 Minuten, eine weitere Kapsel geben.
Nicht empfohlen bei:
• okulärer oder neurologischer FIP.
• Katzen, die nicht normal fressen oder Kot absetzen
• Katzen mit schlechter Nährstoffaufnahme in der Vorgeschichte.
Behandlungsdauer: bis zu 60 Tage oder nach tierärztlicher Empfehlung.
Lagerung: trocken und kühl, vor Sonnenlicht geschützt.
Verpackung:
Jede Packung enthält 60 Kapseln in einem vakuumversiegelten Mylar-Beutel.
Katzen bis 2,5 kg brauchen 60 Kapseln alle 30 Tage.
Katzen von 2,5 bis 5 kg brauchen 120 Kapseln alle 30 Tage.
Katzen über 5 kg brauchen 180 Kapseln alle 30 Tage.
Haltbarkeit: 12 Monate
Häufige Fragen
What is EIDD-1931?
EIDD-1931 is the active antiviral form of molnupiravir. Because it does not need to be converted in the liver, it avoids much of the liver stress linked to long molnupiravir treatment.
How much do I give?
One capsule every 12 hours for every 2.5 kg of body weight, preferably on an empty stomach: below 2.5 kg, 1 capsule; 2.5 to 5 kg, 2 capsules; above 5 kg, 3 capsules. If your cat vomits within 30 minutes, give another capsule.
How long is the treatment?
Up to 60 days, or as recommended by your veterinarian. We recommend a complete blood panel about every 30 days so your veterinarian can follow the response.
Is it suitable for every type of FIP?
It is formulated for wet (effusive) and dry (non-effusive) FIP. It is not recommended for ocular or neurological FIP, or for cats that are not eating or passing stools normally.
Can it be used in pregnant or breeding cats?
No. EIDD-1931 can harm developing kittens, so it should not be given to pregnant, nursing or breeding cats.
How many packs will I need?
Each pack holds 60 capsules. For 30 days of treatment: up to 2.5 kg, 60 capsules; 2.5 to 5 kg, 120 capsules; above 5 kg, 180 capsules.
Please visit our FAQ page for more useful information.
Versandinformationen
Shipped from your region: We deliver worldwide from our local warehouses in each region, so your order ships from the warehouse closest to you.
Dispatch: All orders are processed and dispatched within 24 hours in secure, tamper-evident and discreet packaging.
Delivery: Every order is tracked. Local deliveries go by trusted express couriers, and international shipments by DHL or FedEx. The shipping options and estimated delivery time for your address are shown at checkout.
Shipping condition: Shipped at ambient temperature in individually packed, air-sealed mylar bags.
Dosierung
Dosierungsanleitung
Unter 2,5 kg: 1 Kapsel alle 12 Stunden
2,5 kg ~ 5 kg: 2 Kapseln alle 12 Stunden
Über 5 kg: 3 Kapseln alle 12 Stunden
Dosierungsbeispiele
• Beispiel 1: Ein 2,0 kg schweres Kätzchen mit effusiver (feuchter) FIP erhält alle 12 Stunden eine Kapsel.
• Beispiel 2: Eine 4,6 kg schwere erwachsene Katze mit nicht effusiver (trockener) FIP erhält alle 12 Stunden zwei Kapseln.
Kontrolle und Nachsorge
Wir empfehlen dringend, bei Ihrer Katze etwa alle 30 Tage ein großes Blutbild machen zu lassen, verbunden mit einer laufenden Beurteilung durch Ihre Haustierärztin oder Ihren Haustierarzt. Regelmäßige Kontrollen ermöglichen es, das Ansprechen zu beurteilen und zu entscheiden, ob die Behandlung fortgesetzt, die Dosis angepasst oder die Therapie beendet wird.
Bewertungen
Noch keine Bewertungen. Haben Sie dieses Produkt gekauft? Teilen Sie als Erstes Ihre Erfahrung.
